Cartesian Therapeutics (RNAC) had its "outperform" rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.
Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by BTIG Research.
Cartesian Therapeutics (RNAC) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $42.00 price target on the stock.
Cartesian Therapeutics (RNAC) was upgraded by Cantor Fitzgerald from "neutral" to "overweight". They now have a $16.00 price target on the stock.
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]